Dissemin is shutting down on January 1st, 2025

Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 9(56), p. 4980-4984, 2012

DOI: 10.1128/aac.01095-12

Links

Tools

Export citation

Search in Google Scholar

Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxyl Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques

Journal article published in 2012 by Koen K. A. Van Rompay, Darius Babusis ORCID, Zachary Abbott, Yongzhi Geng, Kartika Jayashankar, Jeffrey A. Johnson, Jonathan Lipscomb, Walid Heneine, Kristina Abel, Adrian S. Ray
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate (TDF) versus subcutaneous tenofovir (TFV), macaques were treated for 2 weeks starting 1 week after simian immunodeficiency virus inoculation. Despite lower plasma TFV levels in the oral TDF arm, similar TFV diphosphate levels and antiviral activities were measured in lymphoid cells of most tissues. In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels and better immune preservation.